Arca
Skip to content
Tools
Tools

TRPV1: Transient receptor potential cation channel subfamily V member 1

Non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli.

  • Drugs that act on it: 18
  • Approved: 2
  • In phases 1 to 3: 16
  • Sponsors: 12

Who is on it, and how far along

Every drug ChEMBL records acting on TRPV1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 13
  • Other 5

Approved2

  • Acetaminophen
  • Capsaicin

Phase 33

  • Resiniferatoxin
  • PAC-14028
  • Zucapsaicin

Phase 29

  • AZD1386
  • DWP05195
  • GRC-6211
  • JTS-653
  • Mavatrep
  • NGD-8243
  • SAF312
  • SB-705498
  • XEN-D0501

Phase 14

  • ABT-102
  • AMG-517
  • MR-1817
  • PHE377

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 13 of 18 act as: Vanilloid receptor antagonist; the rest name their own mechanism.
AcetaminophenBoxed warningApprovedPolyMedicaSmall moleculeOpenerVanilloid receptor opener388
CapsaicinApprovedAveritas PharmaSmall moleculeOpenerVanilloid receptor opener39
ResiniferatoxinPhase 3Grünenthal GmbHSmall moleculeAgonistVanilloid receptor agonist2
PAC-14028Phase 3Amorepacific CorporationOtherAntagonist0
ZucapsaicinPhase 3Winston LaboratoriesSmall moleculeAgonistVanilloid receptor agonist0
AZD1386Phase 2AstraZeneca PharmaceuticalsSmall moleculeAntagonist0
DWP05195Phase 2Daewoong PharmaceuticalSmall moleculeAntagonist0
GRC-6211Phase 2—Small moleculeAntagonist0
JTS-653Phase 2—Small moleculeAntagonist0
MavatrepPhase 2Johnson & JohnsonSmall moleculeAntagonist0
NGD-8243Phase 2Merck & Co. (MSD)Small moleculeAntagonist0
SAF312Phase 2Novartis PharmaceuticalsOtherInhibitorVanilloid receptor inhibitor0
SB-705498Phase 2GSKSmall moleculeAntagonist0
XEN-D0501Phase 2Pila PharmaOtherAntagonist0
ABT-102Phase 1—Small moleculeAntagonist0
AMG-517Phase 1—Small moleculeAntagonist0
MR-1817Phase 1—OtherAntagonist0
PHE377Phase 1—OtherAntagonist0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.
A Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced FeverAcetaminophenPhase 3RecruitingKenvue Brands LLCNov 19, 2026
Oral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy VolunteersCapsaicinNot applicableNot yet recruitingDove Medical Press LtdNov 19, 2026
Erector Spinae Plane Block Versus External Oblique Intercostal Plus Lateral External Oblique Muscle Plane Block in Laparoscopic Living Donor NephrectomyAcetaminophenNot applicableNot yet recruitingIstanbul Medipol University HospitalNov 18, 2026
Intrathecal Morphine 200 Micrograms Versus 450 Micrograms After Major Open Urologic SurgeryAcetaminophenPhase 4Not yet recruitingClinical Hospital Centre ZagrebNov 17, 2026
Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling.AcetaminophenPhase 4RecruitingLiverpool John Moores UniversityNov 13, 2026
Hybrid Parasternal Intercostal Plane Block Versus No Block for Postoperative Analgesia After Cardiac Surgery Via Median SternotomyAcetaminophenNot applicableNot yet recruitingSeo-hee LeeNov 12, 2026
A Retrospective Study to Assess Patient-Reported Treatment Experience With Over-the-Counter Analgesic ProductsAcetaminophen—Not yet recruitingHALEONNov 12, 2026
Physical Therapy for the Management of Postoperative Pain After Minimally Invasive Thoracic SurgeryAcetaminophenPhase 4Not yet recruitingUniversity of MiamiNov 12, 2026
A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee ArthroplastyAcetaminophenPhase 4Not yet recruitingUniversity of California, IrvineNov 10, 2026
Effects of a Preoperative Capsaicin-Containing Diet on Postoperative Liver Injury RepairCapsaicinNot applicableNot yet recruitingTongji HospitalNov 9, 2026
High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral NeuropathyCapsaicinPhase 4Not yet recruitingCase Comprehensive Cancer CenterSep 22, 2026
Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyCapsaicinPhase 4Not yet recruitingUniversity of MichiganAug 31, 2026
Marsili Syndrome as a Gateway to Novel Analgesic TargetsCapsaicinNot applicableActive, not recruitingAalborg UniversityAug 10, 2026
TaVNS for Capsaicin-Induced PainCapsaicinNot applicableNot yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineJul 22, 2026
Pain Beliefs and Intracortical Excitability During Experimental PainCapsaicinNot applicableNot yet recruitingUniversité de SherbrookeJul 7, 2026
Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin PatchesCapsaicinNot applicableNot yet recruitingNantes University HospitalJun 22, 2026
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)ResiniferatoxinPhase 1RecruitingPaolo Caimi, MDNov 6, 2025
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone PainResiniferatoxinPhase 1 / Phase 2Not yet recruitingNational Institute of Neurological Disorders and Stroke (NINDS)Aug 13, 2015

Diseases most associated with it

Open Targets association score, 0 to 1; all associations

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4794, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q8NER1, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.